The story of Viagra presents a complex picture for shareholders. While the initial introduction generated substantial returns, the lapse of its patent opened the door to off-brand versions, dramatically reducing market share. This poses a particular risk for drug manufacturers banking on related

The emergence of so-called "Elite Gambler's Sildenafil" – often referring to exceptionally high doses ordered by unscrupulous physicians – represents a particularly alarming trend. While standard dosages of Sildenafil are intended for treating erectile dysfunction safely in most men, these signif